ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1

FEBS Journal

Volumn 275, Issue 19, 2008, Pages 4875-4886

  Stevens, Craig ^a   Pettersson, Susanne ^a   Wawrzynow, Bartosz ^a   Wallace, Maura ^b   Ball, Kathryn ^a   Zylicz, Alicja ^c   Hupp, Ted R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

Author keywords

ATP; Chaperone; E2F; MDM2; p53

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHAPERONE; DIMETHYL SULFOXIDE; PROTEIN ANTIBODY; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DNA BINDING; DNA SYNTHESIS INHIBITION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; HUMANS; MICE; MOLECULAR CHAPERONES; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; UBIQUITIN-PROTEIN LIGASES;

MURINAE;

EID: 51749084203     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06627.x     Document Type: Article

References (43)

1. Barral JM, Broadley SA, Schaffar G Hartl FU (2004) Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 15, 17 29.
2. Mosser DD Morimoto RI (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23, 2907 2918.
3. Westerheide SD Morimoto RI (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 280, 33097 33100.
4. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW et al. (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63, 8984 8995.
5. Kamal A, Boehm MF Burrows FJ (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10, 283 290.
6. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407 410.
7. Ciocca DR Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10, 86 103.
8. Neckers L Neckers K (2005) Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 10, 137 149.
9. Pacey S, Banerji U, Judson I Workman P (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172, 331 358.
10. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A Oren M (1986) Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320, 182 184.
11. Sepehrnia B, Paz IB, Dasgupta G Momand J (1996) Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 271, 15084 15090.
12. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD Cook PH (1998) The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18, 1517 1524.
13. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV Neckers L (1997) Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14, 2809 2816.
14. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A Zylicz M (2004) Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279, 48836 48845.
15. Zylicz M, King FW Wawrzynow A (2001) Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20, 4634 4638.
16. King FW, Wawrzynow A, Hohfeld J Zylicz M (2001) Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J 20, 6297 6305.
17. Blagosklonny MV (2002) p53: an ubiquitous target of anticancer drugs. Int J Cancer 98, 161 166.
18. Blagosklonny MV, Toretsky J Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11, 933 939.
19. Muller P, Ceskova P Vojtesek B (2005) Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem 280, 6682 6691.
20. Peng Y, Chen L, Li C, Lu W Chen J (2001) Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 276, 40583 40590.
21. Burch L, Shimizu H, Smith A, Patterson C Hupp TR (2004) Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol 337, 129 145.
22. Wawrzynow B, Zylicz A, Wallace M, Hupp T Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chem 282, 32603 32612.
23. Poyurovsky MV, Jacq X, Ma C, Karin-Schmidt O, Parker PJ, Chalfie M, Manley JL Prives C (2003) Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol Cell 12, 875 887.
24. Wallace M, Worrall E, Pettersson S, Hupp TR Ball KL (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23, 251 263.
25. Hansen S, Hupp TR Lane DP (1996) Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J Biol Chem 271, 3917 3924.
26. Brown CR, Hong-Brown LQ Welch WJ (1997) Correcting temperature-sensitive protein folding defects. J Clin Invest 99, 1432 1444.
27. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS Welch WJ (1996) Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1, 117 125.
28. Chen J, Marechal V Levine AJ (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13, 4107 4114.
29. Haupt Y, Maya R, Kazaz A Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296 299.
30. Shimizu H, Saliba D, Wallace M, Finlan L, Langridge-Smith PR Hupp TR (2006) Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J 397, 355 367.
31. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL Hupp TR (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277, 28446 28458.
32. Stevens C La Thangue NB (2003) E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412, 157 169.
33. Martin K, Trouche D, Hagemeier C, Sorenson TS, La Thangue NB Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691 694.
34. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K Xiao Z-XJ (2004) The central acidic domain of MDM2 is critical in inhibition of retinoblastoma- mediated suppression of E2F and cell growth. J Biol Chem 279, 53317 53322.
35. Zang Z, Wang H, Li M, Rayburn ER, Agrawal S Zhang R (2005) Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24, 7238 7247.
36. Kowalik TF, DeGregori J, Leone G, Jakoi L Nevins JR (1998) E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 9, 113 118.
37. Blattner C, Sparks A Lane D (1999) Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 19, 3704 3713.
38. Loughran O La Thangue NB (2000) Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 20, 2186 2197.
39. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S Schwartz GK (2006) Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26, 3473 3481.
40. Wunderlich M Berberich SJ (2002) Mdm2 inhibition of p53 induces E2F1 transactivation via p21. Oncogene 21, 4414 4421.
41. Esser C, Scheffner M Hohfeld J (2005) The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 280, 27443 27448.
42. Strachan GD, Jordan-Sciutto KL, Rallapalli R, Tuan RS Hall DJ (2003) The E2F-1 transcription factor is negatively regulated by its interaction with the MDMX protein. J Cell Biochem 88, 557 568.
43. Wunderlich M, Ghosh M, Weghorst K Berberich SJ (2004) MdmX represses E2F1 transactivation. Cell Cycle 3, 472 478.